| II-19 Rolien Bosch Linking 4GI Glucose Homeostasis and Hall Body Composition Models to study GLP-1R Agonist effects on glucose and body weight Wednesday 15:35-17:00 |
| II-43 Marwa Elhefnawy Quantifying the rate of blood glucose changes over the acute stage of ischemic stroke among patients with diabetes. Wednesday 15:35-17:00 |
| II-45 Edoardo Faggionato Assessing insulin sensitivity, glucose effectiveness, and β-cell responsivity using an integrated glucose, insulin, and C-peptide minimal model Wednesday 15:35-17:00 |
| II-56 Benjamin Guiastrennec Model-Based Translational Rapamycin Dose Selection to Promote Engraftment and Expansion of the Engineered Regulatory T cell (EngTreg) product GNTI-122 in Human Wednesday 15:35-17:00 |
| II-79 Hanna Kunina Blood glucose profile evaluation with model-based approach using continuous glucose monitoring data Wednesday 15:35-17:00 |
| II-83 Rune Overgaard Similar efficacy and gastrointestinal tolerability versus exposure for oral and subcutaneous semaglutide Wednesday 15:35-17:00 |
| II-89 Nelleke Snelder From glomerular filtration rate to renal composite endpoint: an integrated time-to-event analysis of finerenone in phase 3 studies. Wednesday 15:35-17:00 |
| II-91 Britta Steffens Enhanced pharmacometrics model utilizes heart rate to monitor thyroid function in pediatric Graves’ disease under pharmacotherapy Wednesday 15:35-17:00 |
